T 细胞结合双特异性抗体（T-BsAb）：从技术到治疗学。
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.
机构信息
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
出版信息
Pharmacol Ther. 2018 Feb;182:161-175. doi: 10.1016/j.pharmthera.2017.08.005. Epub 2017 Aug 20.
Abstract
Harnessing the power of the human immune system to treat cancer is the essence of immunotherapy. Monoclonal antibodies engage the innate immune system to destroy targeted cells. For the last 30years, antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity have been the main mechanisms of anti-tumor action of unconjugated antibody drugs. Efforts to exploit the potentials of other immune cells, in particular T cells, culminated in the recent approval of two T cell engaging bispecific antibody (T-BsAb) drugs, thereby stimulating new efforts to accelerate similar platforms through preclinical and clinical trials. In this review, we have compiled the worldwide effort in exploring T cell engaging bispecific antibodies. Our special emphasis is on the lessons learned, with the hope to derive insights in this fast evolving field with tremendous clinical potential.
摘要
利用人体免疫系统治疗癌症是免疫疗法的本质。单克隆抗体利用先天免疫系统来摧毁靶向细胞。在过去的 30 年中，抗体依赖性细胞介导的细胞毒性和补体依赖性细胞毒性一直是未缀合抗体药物抗肿瘤作用的主要机制。利用其他免疫细胞（特别是 T 细胞）潜力的努力最终促成了两种 T 细胞结合双特异性抗体（T-BsAb）药物的最近批准，从而刺激了通过临床前和临床试验加速类似平台的新努力。在这篇综述中，我们汇集了全球探索 T 细胞结合双特异性抗体的努力。我们特别强调所吸取的经验教训，希望从这个具有巨大临床潜力的快速发展领域中获得一些见解。
相似文献
1
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.T 细胞结合双特异性抗体（T-BsAb）：从技术到治疗学。
Pharmacol Ther. 2018 Feb;182:161-175. doi: 10.1016/j.pharmthera.2017.08.005. Epub 2017 Aug 20.
2
In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.使用双特异性抗体（抗CD3×抗独特型）以及CD28诱导的共刺激对BCL1淋巴瘤进行的体内研究。
J Hematother. 1995 Oct;4(5):363-8. doi: 10.1089/scd.1.1995.4.363.
3
Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.CD3xCD19双特异性单克隆抗体在B细胞恶性肿瘤中的性能
Leuk Lymphoma. 1995 Nov;19(5-6):381-93. doi: 10.3109/10428199509112195.
4
Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.双特异性抗体在两种白血病复发模型中靶向作用于具有肿瘤特异性的抗原。
Blood. 1996 Dec 15;88(12):4651-8.
5
Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.NK 细胞衔接双特异性抗体治疗癌症的原则和临床现状。
Hum Vaccin Immunother. 2023 Aug;19(2):2256904. doi: 10.1080/21645515.2023.2256904. Epub 2023 Sep 29.
6
7
Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.亲和力对双特异性抗体结合 T 细胞功能的二分影响。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002444.
8
Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.调节肿瘤浸润髓系细胞以增强双特异性抗体驱动的 T 细胞浸润和抗肿瘤反应。
J Hematol Oncol. 2021 Sep 8;14(1):142. doi: 10.1186/s13045-021-01156-5.
9
Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy.利用细胞毒性颗粒胞吐作用来增强 T 细胞结合双特异性抗体治疗的疗效。
Haematologica. 2024 Jul 1;109(7):2131-2143. doi: 10.3324/haematol.2023.284435.
10
Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.利用双特异性T细胞衔接器（BiTE）平台进行癌症免疫治疗。
Expert Opin Biol Ther. 2015;15(8):1093-9. doi: 10.1517/14712598.2015.1041373. Epub 2015 May 13.
引用本文的文献
1
Phenotypic and targeted drug discovery in immune therapeutics: challenges, opportunities, and future directions.免疫治疗中的表型和靶向药物发现：挑战、机遇与未来方向。
RSC Adv. 2025 Aug 22;15(36):29937-29951. doi: 10.1039/d5ra03914b. eCollection 2025 Aug 18.
2
Design of a prodrug bispecific antibody masked by a functional molecule for lymphocyte activation for cancer therapy.一种用于癌症治疗的、由功能性分子掩盖的前药双特异性抗体的设计，用于淋巴细胞激活。
J Biol Eng. 2025 May 15;19(1):45. doi: 10.1186/s13036-025-00517-9.
3
Migrasomes as intercellular messengers: potential in the pathological mechanism, diagnosis and treatment of clinical diseases.迁移小体作为细胞间信使：在临床疾病病理机制、诊断和治疗中的潜力
J Nanobiotechnology. 2025 Apr 20;23(1):302. doi: 10.1186/s12951-025-03362-6.
4
Bispecific antibodies targeting MPXV A29 and B6 demonstrate efficacy against MPXV infection.靶向猴痘病毒A29和B6的双特异性抗体对猴痘病毒感染具有疗效。
J Virol. 2025 May 20;99(5):e0232024. doi: 10.1128/jvi.02320-24. Epub 2025 Apr 3.
5
A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer.一种靶向ROR1的双特异性T细胞衔接器在三阴性乳腺癌临床前模型中显示出高效能。
Breast Cancer Res. 2025 Mar 31;27(1):47. doi: 10.1186/s13058-025-02005-w.
6
The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.双特异性抗体在B细胞非霍奇金淋巴瘤中的研发与应用
J Pers Med. 2025 Jan 28;15(2):51. doi: 10.3390/jpm15020051.
7
Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer.自然杀伤T细胞和γδT细胞在间皮素靶向胰腺癌免疫治疗中的疗效。
Front Immunol. 2025 Feb 10;16:1524899. doi: 10.3389/fimmu.2025.1524899. eCollection 2025.
8
Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.双特异性抗体作为治疗泌尿系统癌症的强大免疫治疗剂：基于临床前和临床证据的最新创新
Int J Biol Sci. 2025 Jan 27;21(4):1410-1435. doi: 10.7150/ijbs.96155. eCollection 2025.
9
Emerging strategies to overcome ovarian cancer: advances in immunotherapy.克服卵巢癌的新兴策略：免疫疗法的进展
Front Pharmacol. 2024 Nov 5;15:1490896. doi: 10.3389/fphar.2024.1490896. eCollection 2024.
10
Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma.集成成像探针和双特异性抗体的开发实现了对表达磷脂酰肌醇蛋白聚糖-3的肝细胞癌的体内靶向。
Mol Cancer Ther. 2024 Dec 3;23(12):1815-1826. doi: 10.1158/1535-7163.MCT-23-0470.
本文引用的文献
1
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.PF-06671008的研发，一种高效的抗P-钙黏蛋白/抗CD3双特异性DART分子，具有延长的半衰期用于癌症治疗。
Antibodies (Basel). 2016 Mar 4;5(1):6. doi: 10.3390/antib5010006.
2
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.用新型HER2/CD3双特异性抗体克服对HER2靶向治疗的耐药性。
Oncoimmunology. 2017 Mar 10;6(3):e1267891. doi: 10.1080/2162402X.2016.1267891. eCollection 2017.
3
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.膜近端表位促进抗FcRH5/CD3高效形成T细胞突触，且是杀伤骨髓瘤细胞的必要条件。
Cancer Cell. 2017 Mar 13;31(3):383-395. doi: 10.1016/j.ccell.2017.02.001. Epub 2017 Mar 2.
4
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.BCMA-T 细胞双特异性抗体 EM801 用于多发性骨髓瘤治疗的靶表达、生成、临床前活性和药代动力学。
Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2.
5
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies.滤泡性CD8 T细胞在HIV感染中会积聚，并且在体外可通过双特异性抗体杀死被感染的细胞。
Sci Transl Med. 2017 Jan 18;9(373). doi: 10.1126/scitranslmed.aag2285.
6
The making of bispecific antibodies.双特异性抗体的制备。
MAbs. 2017 Feb/Mar;9(2):182-212. doi: 10.1080/19420862.2016.1268307.
7
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.一种新型的 BCMA/CD3 双特异性 T 细胞衔接子，用于治疗多发性骨髓瘤，可在体外和体内诱导选择性裂解。
Leukemia. 2017 Aug;31(8):1743-1751. doi: 10.1038/leu.2016.388. Epub 2016 Dec 27.
8
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.一种用于治疗急性髓系白血病的抗CD3/抗CLL-1双特异性抗体。
Blood. 2017 Feb 2;129(5):609-618. doi: 10.1182/blood-2016-08-735365. Epub 2016 Dec 1.
9
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.双特异性T细胞衔接器（BiTE）介导的针对CD19+儿童急性淋巴细胞白血病的T细胞反应受到白血病母细胞上PD-L1和CD80/CD86的相反调节。
Oncotarget. 2016 Nov 22;7(47):76902-76919. doi: 10.18632/oncotarget.12357.
10
MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies.MGD011，一种包含延长循环半衰期的 CD19 x CD3 双特异性重定向双功能分子，用于治疗 B 细胞恶性肿瘤。
Clin Cancer Res. 2017 Mar 15;23(6):1506-1518. doi: 10.1158/1078-0432.CCR-16-0666. Epub 2016 Sep 23.
Zotero 插件